Immuneering Corp
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA, 02142
Mailing Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA, 02142
Phone
617-500-8080
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$56.02M
Net Income
$231.99M
Total Assets
$13.50M
Total Liabilities
$218.48M
Stockholders' Equity
$128.65M
Cash & Equivalents
$-1.27
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 10-K Annual financial report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
Annual Reports
10-K
March 6, 2026
- Clinical-stage biotech focused on small molecule cancer treatments, leveraging a proprietary Deep-rooted tumor biology platform.
- Lead drug candidate Atebimetinib (IMM-1-104) is in clinical development for advanced solid tumors, with Envometinib (IMM-6415) also progressing.
Insider Trading
BUY
5 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.